Prothena | PRTA - Current Assets

Stock Price
9.21
Daily Change
-0.10 -1.07%
Monthly
2.79%
Yearly
-32.97%
Q1 Forecast
8.93

Prothena reported $339.97M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Akebia Therapeutics USD 252.96M 5.38M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Exelixis USD 1.44B 41.03M Dec/2025
Immunic USD 39.27M 20.57M Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Prothena USD 339.97M 45.51M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xoma USD 110.71M 5.78M Sep/2025